Overseas, the importance for breast MRI screening for high-risk groups has been shown. However, the evidence among Japanese population was lacking. Therefore, we collaborated with the “Study on clinical and genetic characterization of hereditary breast and ovarian cancer and improvement in prognosis using genetic information in Japan” group, as part of the Comprehensive Research Project on the Promotion of Cancer Control, Health and Labour Sciences Research, and have been conducting the study entitled, “Study of the usefulness of MRI surveillance of BRCA1/2 mutation carriers” since 2014. In addition, we found that in the Japanese population also, the pathological and imaging characteristics differ between BRCA1 and BRCA2 mutation carriers, like in non-Japanese populations by the several reports. In high-risk females, risk categories such as BRCA1 or BRCA2 mutation carriers are very important. Furthermore, in the future, the optimal surveillance modalities and examination intervals would also vary according to the age, thinness of the breast (constitution), breast density (individual differences on mammography), etc.; this would be “personalized surveillance”, and quality-assured MRI examination is of the essence. This review will present clinical trial data of prospective MRI surveillance in Japan, and summarize the current status of breast cancer screening in high-risk Japanese women.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Arai M, Yokoyama S, Watanabe C, Yoshida R, Kita M, Okawa M, et al. Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan. J Hum Genet. 2018;63:447–57.
Guidelines for the optimal use of breast MRI for screening of breast cancer in high-risk women, the Japan Association of Breast Cancer Screening. https://www.jabcs.jp/images/mri_guideline_fix.pdf. Accessed 3 July 2020.
Taira N, Arai M, Ikeda M, Iwasaki M, Okamura H, Takamatsu K, et al. The Japanese Breast Cancer Society clinical practice guideline for epidemiology and prevention of breast cancer. Breast Cancer. 2015;22:16–27.
Taira N, Arai M, Ikeda M, Iwasaki M, Okamura H, Takamatsu K, et al. The Japanese Breast Cancer Society clinical practice guidelines for epidemiology and prevention of breast cancer, 2015 edition. Breast Cancer. 2016;23:343–56.
Guidebook for diagnosis and treatment of Hereditary Breast and Ovarian Cancer Syndrome 2017, Kanehara shuppan 2017.
Uematsu T, Nakashima K, Kikuchi M, Kubota K, Suzuki A, Nakano S, et al. The Japanese Breast Cancer Society Clinical Practice Guidelines for breast cancer screening and diagnosis, 2018 edition. Breast Cancer. 2020;27:17–24.
Tozaki M. Significance of breast MRI for high-risk groups. J Jpn Assoc Breast Cancer Screen. 2020;29:15–20.
American College of Radiology. Breast imaging reporting and data system (BI-RADS). 5th ed. Reston: American College of Radiology; 2013.
Tozaki M, Fukuma E. 1H MR spectroscopy and diffusion-weighted imaging of the breast: are they useful tools for characterizing breast lesions before biopsy? AJR Am J Roentgenol. 2009;193(3):840–9.
Tozaki M, Nakamura S, Kitagawa D, Iwase T, Horii R, Akiyama F, et al. Ductal carcinoma in situ detected during prospective MR imaging screening of a woman with a BRCA2 mutation: the first case report in Japan. Magn Reson Med Sci. 2017;16:265–9.
Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004;292:1317–25.
Vreemann S, Gubern-Mérida A, Schlooz-Vries MS, Bult P, van Gils CH, Hoogerbrugge N, et al. Influence of risk category and screening round on the performance of an MR imaging and mammography screening program in carriers of the BRCA mutation and other women at increased risk. Radiology. 2018;286:443–51.
Kuhl C, Weigel S, Schrading S, Arand B, Bieling H, König R, et al. Prospective multicenter cohort study to refine managements recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol. 2010;28:1450–7.
Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317:2402–16.
Schrading S, Kuhl CK. Mammographic, US and MR imaging phenotypes of familial breast cancer. Radiology. 2008;246:58–70.
Rijnsburger AJ, Obdeijn IM, Kaas R, Kaas R, Tilanus-Linthorst MM, Boetes C, et al. BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. J Clin Oncol. 2010;28:5265–73.
Heijnsdijk EA, Warner E, Gilbert FJ, Tilanus-Linthorst MM, Evans G, Causer PA, et al. Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined. Cancer Epidemiol Biomarkers Prev. 2012;21:1458–68.
Nakamura S, Takahashi M, Tozaki M, Nakayama T, Nomizu T, Miki Y, et al. Prevalence and differentiation of hereditary breast and ovarian cancers in Japan. Breast Cancer. 2015;22:462–8.
Murakami W, Tozaki M, Nakamura S, Ide Y, Inuzuka M, Hirota Y, et al. The clinical impact of MRI screening for BRCA mutation carriers: the first report in Japan. Breast Cancer. 2019;26:552–61.
Obdeijn IM, Winter-Warnars GA, Mann RM, Hooning MJ, Hunink MG, Tilanus-Linthorst MM. Should we screen BRCA1 mutation carriers only with MRI? A multicenter study. Breast Cancer Res Treat. 2014;144:577–82.
Vreemann S, van Zelst JCM, Schlooz-Vries M, Bult P, Hoogerbrugge N, Karssemeijer N, et al. The added value of mammography in different age-groups of women with and without BRCA mutation screened with breast MRI. Breast Cancer Res. 2018;20:84.
We are grateful to Dr. Akihiro Sakurai (Sapporo Medical University), Dr. Masami Arai (Juntendo University, Graduate School of Medicine), Dr. Hideko Yamauchi (St. Luke’s International Hospital) and Dr. Dai Kitagawa (Cancer Institute Hospital) for supporting the prospective clinical study.
This work was supported by Health, Labour and Welfare Sciences Research Grants (H26-policy for cancer-general-012) and (H29-policy for cancer-general-003).
Conflict of interest
The authors declare that they have no conflicts of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This paper is modified from the manuscript “Significance of breast MRI for high-risk groups” (J. Jpn. Assoc. Breast Cancer Screen.) 2020, 29(1) MAR 15, with permission from the original publisher.
About this article
Cite this article
Tozaki, M., Nakamura, S. Current status of breast cancer screening in high-risk women in Japan. Breast Cancer (2020). https://doi.org/10.1007/s12282-020-01103-1
- Hereditary breast and ovarian cancer syndrome
- Breast cancer screening
- Magnetic resonance imaging